. Author manuscript; available in PMC: 2020 Apr 15.

Published in final edited form as: Clin Cancer Res. 2019 Jul 29;25(20):6089–6097. doi: 10.1158/1078-0432.CCR-19-0208

Table 1.

Incidence of single CTC, doublets(s), and cluster(s) at baseline

	Baseline	Single CTC (no Doublets or Clusters)			CTC with Doublets or Clusters present
A. Incidence of single CTC, doublets(s), and cluster(s) at baseline using the revised CellSearch® algorithm.
	Baseline	0 CTC	1–4 CTC	≥5 CTC	Doublet(s) only	Cluster(s) only	Doublet(s) and Cluster(s)	Any Doublet(s) or Cluster(s)
All	N=549	158 (29%)	120 (22%)	167 (30%)	58 (11%)	11 (2%)	35 (6%)	104 (19%)
Arm A	N=283	158 (56%)	120 (42%)	1 (<1%)	3 (1%)	0	1 (<1%)	4 (1.4%)
Arm B/C	N=266	NA	NA	166 (62%)	55 (21%)	11 (4%)	34 (13%)	100 (38%)
Arm B	N=154	NA	NA	115 (75%)	20 (13%)	4 (2%)	15 (10%)	39 (25%)
Arm C	N= 112	NA	NA	51 (46%)	35 (31%)	7 (6%)	19 (17%)	61 (54%)
p-value of presence of doublets or clusters comparing Arm B/C vs. Arm A: < 0.0001; p-value of presence of doublets or clusters comparing Arm B vs. Arm C: < 0.0001.
B. Incidence of doublets, clusters, doublets and/or clusters at baseline by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status in primary cancer.
	Baseline	Single CTC (no Doublets nor Clusters)			CTC with Doublets or Clusters present
	Baseline	0 CTC	1–4 CTC	≥5 CTC	Doublet(s) only	Cluster(s) only	Doublet(s) and Cluster(s)	Any Doublet(s) or Cluster(s)
All	N=545^a	157 (29%)	120 (22%)	164 (30%)	58 (11%)	11 (2%)	35 (6%)	104 (19%)
HR pos; HER2 neg	N=320	81 (25%)	72 (22%)	101 (32%)	37 (12%)	10 (3%)	19 (6%)	66 (21%)
HER2 pos	N=95	30 (32%)	23 (24%)	26 (27%)	11 (12%)	1 (1%)	4 (4%)	16 (17%)
Triple negative	N=130	46 (35%)	25 (19%)	37 (29%)	10 (8%)	0	12 (9%)	22 (17%)
^aFour patients with missing data; Chi-square test for the presence of doublets according to breast cancer type: p=0.93; Chi-square test for the presence of doublets and/or clusters between breast cancer subtype and clusters: p=0.55.
C. Incidence of doublets, clusters, doublets and/or clusters at baseline by sites of metastases.
	Baseline	Single CTC (no Doublets nor Clusters)			CTC with Doublets or Clusters present
	Baseline	0 CTC	1–4 CTC	≥5 CTC	Doublet(s) only	Cluster(s) only	Doublet(s) and Cluster(s)	Any Doublet(s) or Cluster(s)
All	N=547^a	156 (29%)	120 (22%)	167 (30%)	58 (11%)	11 (2%)	35 (6%)	104 (19%)
Bone only	N=66	20 (30%)	15 (22%)	21 (32%)	4 (6%)	3 (5%)	3 (5%)	10 (15%)
Visceral	N=372	97 (26%)	74 (20%)	123 (33%)	43 (11%)	6 (2%)	29 (8%)	78 (21%)
Other	N=109	39 (36%)	31 (28%)	23 (21%)	11 (10%)	2 (2%)	3 (3%)	16 (15%)

Two patients with missing data. Chi-square test for presence of doublets according sites of metastases: p=0.10 Chi-square test for presence of any doublets or clusters according to sites of metastases: p=0.24.